Pfizer. U.S. FDA approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the treatment of adults and adolescents with hemophilia A or B without inhibitors [media release]. 11 Oct 2024. https://www.pfizer.com/.

Pfizer Inc. HYMPAVZI (marstacimab-hncq) injection, for subcutaneous use. 2024. https://labeling.pfizer.com/ShowLabeling.aspx?id=20916. Accessed 18 Oct 2024.

U.S. Food & Drug Administration. FDA approves new treatment for hemophilia A or B [media release]. 11 Oct 2024. https://www.fda.gov/.

Centers for Disease Control and Prevention. Hemophilia. 2024. https://www.cdc.gov/hemophilia/. Accessed 14 Oct 2024.

Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis. 2012;7(1):1–8.

Article  Google Scholar 

Nogami K, Shima M. Current and future therapies for haemophilia-beyond factor replacement therapies. Br J Haematol. 2023;200(1):23–34.

Article  CAS  PubMed  Google Scholar 

Mancuso ME, Croteau SE, Klamroth R. Benefits and risks of non-factor therapies: redefining haemophilia treatment goals in the era of new technologies. Haemophilia. 2024;30(S3):39–44.

Article  PubMed  Google Scholar 

Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adher. 2017;11:1677–86.

Article  Google Scholar 

Young G. Nonfactor therapies for hemophilia. HemaSphere. 2023;7(6):1–4.

Article  Google Scholar 

Patel-Hett S, Martin EJ, Mohammed BM, et al. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia. 2019;25(5):797–806.

Article  CAS  PubMed  Google Scholar 

Mahlangu J, Luis Lamas J, Cristobal Morales J, et al. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: phase II study results. Br J Haematol. 2023;200(2):240–8.

Article  CAS  PubMed  Google Scholar 

Parng C, Singh P, Pittman DD, et al. Translational pharmacokinetic/pharmacodynamic characterization and target-mediated drug disposition modeling of an anti–tissue factor pathway inhibitor antibody, PF-06741086. J Pharm Sci. 2018;107(7):1995–2004.

Article  CAS  PubMed  Google Scholar 

Pfizer Inc. European Commission approves Pfizer's HYMPAVZI™ (marstacimab) for the treatment of adults and adolescents with severe hemophilia A or B without inhibitors [media release]. 20 Nov 2024. https://www.pfizer.com/.

World Intellectual Property Organisation (WIPO). Dosage regimen for tfpi antagonists. 2020. https://patents.google.com/patent/WO2020075083A1/. Accessed 26 Sep 2024.

World Intellectual Property Organisation (WIPO). Stable aqueous anti-tfpi antibody formulation. 2021. https://patents.google.com/patent/WO2021094917A1/. Accessed 26 Sep 2024.

Cardinal M, Kantaridis C, Zhu T, et al. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers. J Thromb Haemost. 2018;16(9):1722–31.

Article  CAS  PubMed  Google Scholar 

Sun X, Liu W, Luo B, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of marstacimab in Chinese participants with severe haemophilia. Haemophilia. 2023;29(4):1155–9.

Article  CAS  PubMed  Google Scholar 

Mahlangu JN, Lamas JL, Morales JC, et al. A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. Br J Haematol. 2023;200(2):229–39.

Article  CAS  PubMed  Google Scholar 

Pittman DD, Rakhe S, Bowley SR, et al. Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model. Res Pract Thromb Haemost. 2022;6(2):1–10.

Article  Google Scholar 

Raje S, Plotka A, Huyghe I, Teeter J. Bioequivalence (BE) of marstacimab prefilled pen (PFP) device and prefilled syringe (PFS) device following subcutaneous (SC) administration in healthy adult males [abstract no. PO036]. Haemophilia. 2022;28(S1):41–2.

Acharya SS, Matino D, Palladino A, et al. Safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe hemophilia without inhibitors: results from the phase 3 BASIS trial and ongoing long-term extension study [abstract no. 206 + poster]. In: Thrombosis & Hemostasis Societies of North America (THSNA) Summit, April 4–6. 2024.

Matino D, Acharya S, Palladino A, et al. Efficacy and safety of the anti-tissue factor pathway inhibitor marstacimab in participants with severe hemophilia without inhibitors: results from the phase 3 Basis trial [abstract]. Blood. 2023;142(Suppl. 1):285–7.

Article  Google Scholar 

Acharya S, Matino D, Mahlangu J, et al. Marstacimab, an anti-tissue factor pathway inhibitor, in participants with hemophilia Α or B, with and without inhibitors: an integrated analysis of safety [abstract]. Blood. 2023;142(Suppl. 1):3980–2.

Article  Google Scholar 

Teeter J, Charnigo R, Cossons N, et al. Safety and efficacy of marstacimab for prevention of bleeding episodes in paediatric patients with severe haemophilia A or moderately severe to severe haemophilia B with or without inhibitors [abstract no. PO122]. Haemophilia. 2022;28(S1):88–9.